acyclovir and Periodontitis

Topics: Acyclovir; Antiviral Agents; Chronic Disease; Combined Modality Therapy; Female; Humans; Immunocompromised Host; Immunosuppressive Agents; Kidney Transplantation; Middle Aged; Periodontitis; Recurrence; Stomatitis, Herpetic

The aim of this study was to evaluate the clinical benefit of valacyclovir when performing full-mouth periodontal debridement in patients with advanced chronic periodontitis.. Fifty-nine patients with advanced chronic periodontitis were randomly assigned into control-treatment group(n=29) and intensive-treatment group(n=30). All patients were given instructions of basic oral hygiene and a standard cycle of supragingival mechanical scaling and polishing. Patients in the intensive-treatment group received oral valacyclovir for 1 week, while patients in the control-treatment group received placebo. Thereafter, patients in both groups underwent full-mouth intensive removal of subgingival dental plaque biofilms with the use of scaling and root planing within 48 hours. Periodontal parameters were evaluated before treatment and 2 or 6 months after treatment. The data was statistically analyzed using SPSS17.0 software package.. No significant difference in clinical parameters was noted before treatment. 2 and 6 months after treatment, the mean percentage reduction of sites with BOP and PD≥4 mm were significantly higher in the intensive-treatment group than in the control-treatment group (P<0.05). Similarly, patients in the intensive-treatment group had higher mean PD reduction than those in the control-treatment group 2 months (P<0.05) and 6 months after therapy (P<0.05). However, the mean values of CAL reduction were slightly and not significantly higher in the intensive-treatment group than in the control-treatment group after therapy.. It may be concluded that valacyclovir significantly improves clinical results of full-mouth non-surgical periodontal debridement in advanced chronic periodontitis.

Topics: Acyclovir; Biofilms; Chronic Periodontitis; Dental Plaque; Dental Plaque Index; Dental Scaling; Face; Humans; Periodontal Index; Periodontitis; Root Planing; Valacyclovir; Valine

In order to determine the anti-pathogenic clinical efficacy of cycloferon liniment in the combined treatment of herpetic stomatitis and periodontitis, medical examination and treatment of these disorders have been carried out in a group of 80 patients. It is established that the use of cycloferon liniment in the combined treatment of herpetic stomatitis and periodontitis decreases the infectious load in parodontal recess, reduces the manifestations of local inflammation, normalizes the immunity indices, and decreases the level of endogenous intoxication, which ensures the acceleration of recuperation processes and lowers the frequency of recurrences.

Topics: Acridines; Acyclovir; Adult; Candida albicans; Chlamydia trachomatis; Female; Humans; Immunoassay; Immunoglobulin A; Inflammation; Interferon Inducers; Interleukin-1beta; Liniments; Male; Mouth; Periodontitis; Recurrence; Severity of Illness Index; Simplexvirus; Stomatitis, Herpetic; Tumor Necrosis Factor-alpha

It has been suggested that the presence of Epstein-Barr virus (EBV) can increase the severity of marginal periodontitis. We administered antiviral treatment (Valtrex for a period of 10 days) to a patient with recurrent periodontal disease and a high EBV load subgingivally. The antiviral treatment decreased the presence of EBV to the detection limit and the periodontal condition improved dramatically. One year after treatment, the periodontal condition was still stable and the virus barely detectable. The case suggests that virus screening and subsequent antiviral therapy may be useful as an adjunct to conventional periodontal therapy.

Topics: Acyclovir; Antiviral Agents; DNA, Viral; Gingiva; Herpesvirus 4, Human; Humans; Male; Middle Aged; Periodontitis; Polymerase Chain Reaction; Severity of Illness Index; Treatment Outcome; Valacyclovir; Valine

Exposure to cytomegalovirus (CMV) is common in persons infected with the human immunodeficiency virus. Autopsy studies have documented the presence of CMV in multiple organs, but CMV is seldom indicated as the causative agent in specific diseases. Few reports have described localized CMV infection in the oral cavity. This may be due to the occult histopathologic appearance during oral mucosal CMV infections and to a lack of awareness of CMV infection as a potential etiologic agent in nonspecific oral ulcerations and other oral disease entities. This report describes an intraoral ulceration with documented presence of a localized CMV infection in association with human immunodeficiency virus-associated periodontitis in a patient with acquired immunodeficiency syndrome. A causative relationship between these two entities, however, cannot be established or excluded.

Topics: Acyclovir; Adult; Antibodies, Monoclonal; Cytomegalovirus Infections; Cytopathogenic Effect, Viral; HIV Infections; Humans; Inclusion Bodies, Viral; Male; Mouth Mucosa; Periodontitis